

<b>Name of the Issue: CORONA Remedies Limited</b>	
<b>1 Type of Issue</b>	Initial Public offer
<b>2 Offer Size (Rs. Mn)</b>	<b>6,553.71</b>
Fresh Issue Size (Rs. Mn)	-
Offer for Sale (Rs Mn)	6,553.71
<i>*Source: Prospectus for the offer dated December 10, 2025</i>	
<b>3 Grade of issue along with name of the rating agency</b>	
<b>Name</b>	NA
<b>Grade</b>	NA
<b>4 Subscription Level (Number of times)</b>	101.97
<i>* excluding Eligible employee and Eligible shareholder reservation and after removing multiple and duplicate bids and Source: Post Offer Report dated December 17, 2025</i>	

**5 QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges**

Particulars	%
(i) On Allotment in the offer <sup>(1)</sup>	5.00
(ii) at the end of the 1st Quarter immediately after the listing of the issue (period ended December 31, 2025)	8.60
(iii) at the end of 1st FY (March 31, 2026)	9.27
(iv) at the end of 2nd FY (March 31, 2027)*	Not Available
(v) at the end of 3rd FY (March 31, 2028)*	Not Available

*\*QIB Holding not disclosed as reporting for the relevant period/fiscal year has not been completed.*

*(1) Source: Post offer report and BSE website*

**6 Financials of the issuer**

Parameters	<i>(Rs. in Mn)</i>		
	1st FY (March 31, 2026)	2nd FY (March 31, 2027)*	3rd FY (March 31, 2028)*
Income from operations	14,031.80	Not Available	Not Available
Net Profit for the period	1,851.20	Not Available	Not Available
Paid-up equity share capital	611.60	Not Available	Not Available
Reserves excluding revaluation reserves	6,857.00	Not Available	Not Available

*\*Financials not available as reporting for the relevant years has not been completed.*

**7 Trading Status**

The equity shares of CORONA Remedies Limited are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") (and together with BSE the "Stock Exchanges")

The equity shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2026)	Frequently Traded
(ii) at the end of 2nd FY (March 31, 2027)*	Not Available
(iii) at the end of 3rd FY (March 31, 2028)*	Not Available

*\* Trading status not disclosed as the relevant fiscal years have not been completed.*

**8 Change in Directors of Issuer from the disclosures in the offer document<sup>#</sup>**

Particulars	Name of Director	Appointed/Resigned
(i) at the end of 1st FY (March 31, 2026)	Dr. Kirtikumar Mehta (DIN: 00385658)	Re-Appointment
(ii) at the end of 2nd FY (March 31, 2027)*	NA	NA
(iii) at the end of 3rd FY (March 31, 2028)*	NA	NA

*\* Relevant fiscal years have not been completed.*

*# Source - Stock Exchange website*

**9 Status of implementation of project/ commencement of commercial production**

(i) as disclosed in the offer document	Not applicable*
(ii) Actual implementation	Not applicable*
(iii) Reasons for delay in implementation, if any	Not applicable*

*\* Company did not undertake any implementation of project hence the same is not applicable*

**10 Status of utilization of issue proceeds**

The objects of the Offer were to (i) to carry out the Offer for Sale of 6,174,051 Equity Shares of face value of ₹ 10 each by the Selling Shareholders aggregating to ₹ 6,553.71 million; and (ii) achieve the benefits of listing the Equity Shares on the Stock Exchanges.

**11 Comments of monitoring agency, if applicable**

(i) Comments on use of funds	NA
(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the	
(iii) Any other reservations expressed by the monitoring agency about the end use of funds	

12 Pricing Data  
Designated Stock Exchange  
Offer Price (Rs.)  
Listing Date

NSE  
1,062.00  
15-Dec-25

Price parameters	At close of listing day (December 15, 2025)	Close of 30th calendar day from listing day <sup>(2)</sup> (January 13, 2026)	Close of 90th calendar day from listing day <sup>(3)</sup> (March 14, 2026)	As at the end of the 1st FY after the listing of the issue (31st March, 2026) <sup>(4)(5)</sup>		
				Closing price	High (during the FY)	Low (during the FY)
Market Price on NSE <sup>(5)</sup>	1,438.40	1,432.90	1,538.60	1,556.00	1,699.00	1,336.60
Nifty <sup>(5)</sup>	26,268.70	25,732.30	23,151.10	22,331.40	26,373.20	21,743.65
Sectoral Index <sup>(6)</sup>	Not comparable to any of the available sectoral indices			Not comparable to any of the available sectoral indices		
Price parameters	As at the end of the 2nd FY after the listing of the issue (31st March, 2027) <sup>(1)(4)</sup>			As at the end of the 3rd FY after the listing of the issue (31st March, 2028) <sup>(1)(4)</sup>		
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on NSE <sup>(5)</sup>	NA	NA	NA	NA	NA	NA
Nifty <sup>(5)</sup>	NA	NA	NA	NA	NA	NA
Sectoral Index <sup>(6)</sup>	Not comparable to any of the available sectoral indices			Not comparable to any of the available sectoral indices		

\*Source: NSE website

(1) The pricing data is not disclosed as the relevant fiscal years have not been completed

(2) 30th calendar day is taken as listing date plus 29 calendar days

(3) 90th calendar day is taken as listing date plus 89 calendar days

(4) High and Low based on intra day prices

(5) In case of reporting dates falling on a trading holiday, values for the trading day immediately preceding the trading holiday have been considered.

(6) Comparable Sectoral index is not available

13 Basis for Offer Price

Accounting ratio	As disclosed in the offer document <sup>(1)</sup>	At the end of 1st FY (March 31, 2026) <sup>(2)</sup>	At the end of 2nd FY (March 31, 2027) <sup>(3)</sup>	At the end of 3rd FY (March 31, 2028) <sup>(3)</sup>
EPS (₹)	<b>Issuer:</b>			
	Consolidated (Basic)	24.43	30.27	Not Available
	Consolidated (Diluted)	24.43	30.27	Not Available
	<b>Peer Group: (Diluted)</b>			
	Abbott India Limited	665.62	730.36	Not Available
	Alkem Laboratories Limited	181.11	192.51	Not Available
	Eris Lifesciences Limited	25.81	45.26	Not Available
	GlaxoSmithKline Pharmaceuticals Limited	54.76	61.15	Not Available
	J.B. Chemicals & Pharmaceuticals Limited	41.56	44.45	Not Available
	Mankind Pharma Limited	49.20	46.28	Not Available
	Pfizer Limited	167.79	157.92	Not Available
	Sanofi India Limited	179.46	Not Available	Not Available
	Torrent Pharmaceuticals Limited	56.47	63.92	Not Available
	<b>Industry Avg:</b>	<b>157.98</b>	<b>167.73</b>	Not Available
Price to Earnings Ratio (P/E)	<b>Issuer:</b>			
	Consolidated (Consolidated)	NA	51.40	Not Available
	<b>Peer Group (Consolidated)#</b>			
	Abbott India Limited	45.17	35.48	Not Available
	Alkem Laboratories Limited	31.39	27.53	Not Available
	Eris Lifesciences Limited	61.81	28.66	Not Available
	GlaxoSmithKline Pharmaceuticals Limited	46.87	37.33	Not Available
	J.B. Chemicals & Pharmaceuticals Limited	42.60	46.44	Not Available
	Mankind Pharma Limited	45.77	43.34	Not Available
	Pfizer Limited	29.63	29.89	Not Available
	Sanofi India Limited	24.47	Not Available	Not Available
	Torrent Pharmaceuticals Limited	65.91	66.02	Not Available
	<b>Industry Avg:</b>	<b>43.74</b>	<b>39.34</b>	Not Available
	Return on Net Worth (%)	<b>Issuer:</b>		
Consolidated		24.65	24.79%	Not Available
<b>Peer Group: (Consolidated)#</b>				
Abbott India Limited		33.41	32.51	Not Available
Alkem Laboratories Limited		18.07	16.39	Not Available
Eris Lifesciences Limited		12.21	16.62	Not Available
GlaxoSmithKline Pharmaceuticals Limited		47.54	45.69	Not Available
J.B. Chemicals & Pharmaceuticals Limited		19.21	17.06	Not Available
Mankind Pharma Limited		13.89	11.70	Not Available
Pfizer Limited		18.20	17.19	Not Available
Sanofi India Limited		48.05	Not Available	Not Available
Torrent Pharmaceuticals Limited		25.18	12.16	Not Available
<b>Industry Avg:</b>		<b>26.20</b>	<b>21.16</b>	Not Available
NAV per Equity Share (₹ per share)		<b>Issuer:</b>		
	Consolidated	99.14	122.12	Not Available
	<b>Peer Group: (Consolidated)#</b>			
	Abbott India Limited	1992.14	2,246.68	Not Available
	Alkem Laboratories Limited	1002.37	1,200.25	Not Available
Eris Lifesciences Limited	209.73	281.28	Not Available	

GlaxoSmithKline Pharmaceuticals Limited	115.19	133.84	Not Available	Not Available
J.B. Chemicals & Pharmaceuticals Limited	220.88	258.98	Not Available	Not Available
Markind Pharma Limited	352.51	401.19	Not Available	Not Available
Pfizer Limited	921.88	918.67	Not Available	Not Available
Sanofi India Limited	373.68	325.74	Not Available	Not Available
Torrent Pharmaceuticals Limited	224.28	519.56	Not Available	Not Available
<b>Industry Avg:</b>	<b>601.41</b>	<b>698.46</b>	Not Available	Not Available

Revenue from operation for Fiscal 2025 (in ₹million)	<b>Issuer:</b>			
Consolidated	11964.15	14,031.80	Not Available	Not Available
<b>Peer Group: (Consolidated)#</b>				
Abbott India Limited	64,091.50	69,290.50	Not Available	Not Available
Alkem Laboratories Limited	129,645.20	147,122.70	Not Available	Not Available
Eris Lifesciences Limited	28,936.40	31,294.20	Not Available	Not Available
GlaxoSmithKline Pharmaceuticals Limited	37,492.10	38,216.70	Not Available	Not Available
J.B. Chemicals & Pharmaceuticals Limited	39,179.89	41,477.90	Not Available	Not Available
Markind Pharma Limited	122,074.40	142,776.40	Not Available	Not Available
Pfizer Limited	22,813.50	25,196.50	Not Available	Not Available
Sanofi India Limited	20,132.00	Not available	Not Available	Not Available
Torrent Pharmaceuticals Limited	115,160.90	139,800.00	Not Available	Not Available
<b>Industry Avg:</b>	<b>64,391.77</b>	<b>79,396.86</b>	Not Available	Not Available

(1) Source: Prospectus for the offer dated December 10, 2025. #For Abbott India Limited, standalone figures were considered and included in the offer documents.

(2) Information sourced from financials filed by the Issuer Company and Peers on the stock exchanges

(3) Information not provided as the relevant fiscal year has not completed

Key ratios for the Company for the three fiscal years stated above shall be calculated as follows:

1. P/E Ratio has been computed based on the closing market price of equity shares on November 28, 2025, divided by the Diluted EPS.

2. Return on net worth is the restated profit attributable to owners of the Company divided by the net worth at the end of the period/year.

3. Net asset value per equity share as at a period/year represents net worth as of the end of the period/year divided by the weighted average outstanding equity shares considered for EPS as the end of the period/year.

4. J. B. Chemicals & Pharmaceuticals Limited has announced a stock split from ₹2.00 per equity share to ₹1.00 per equity share with ex-split date on September 18, 2023. Accordingly, Net asset value per equity share has been adjusted to reflect the stock split.

#### Any other material information

14

Date	Announcement
Monday, December 15, 2025	Listing of Equity Shares of CORONA Remedies Limited
Monday, December 15, 2025	Closure of Trading Window
Monday, December 15, 2025	Intimation of continuation of Ms. Chetna Dharajya as the Compliance Officer of CORONA Remedies Limited pursuant to Regulation 6(1) of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements), 2015
Monday, December 15, 2025	Intimation of continuation of Bigshare Services Private Limited as the Registrar and Share Transfer Agent of CORONA Remedies Limited
Monday, December 15, 2025	Intimation under Regulation 8(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015
Monday, December 15, 2025	Intimation Under Regulation 30(5) Of The Securities And Exchange Board Of India (Listing Obligation And Disclosures Requirements) Regulation, 2015 - Names of the Key Managerial Personnels of the Company who are authorised to determine the materiality of an event or information and for the purpose of making disclosure to the stock exchanges under Regulation 30 of SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015
Monday, December 15, 2025	Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Commencement of Commercial Production of tablet(s) / capsule(s) at the Bhayla manufacturing facility (Facility) of the Company.
Monday, December 22, 2025	Intimation For Appointment Of Investor Relations Agency - Strategic Growth Advisors Pvt. Ltd
Tuesday, December 23, 2025	Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results On Standalone And Consolidated Basis For The Second Quarter And Half Year Ended On September 30, 2025
Friday, December 26, 2025	Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results On Standalone And Consolidated Basis For The Second Quarter And Half Year Ended On September 30, 2025
Thursday, January 1, 2026	Intimation for updation of CIN of the
Friday, January 2, 2026	Board at its meeting inter alia, approved the unaudited standalone and consolidated financial results along with limited review reports of the Company for the second quarter and half year ended on September 30, 2025.
Friday, January 2, 2026	Intimation of Financial Results for the second quarter and half year ended September 30, 2025
Friday, January 2, 2026	Press Release on financial results for
Saturday, January 3, 2026	Newspaper Publication of Unaudited Financial Results for the second quarter and half year ended September 30, 2025
Tuesday, January 6, 2026	Certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the third quarter ended December 31, 2025
Monday, January 19, 2026	Intimation under Regulation 30-GMP
Tuesday, January 27, 2026	Corona Remedies Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/02/2026 inter alia, to consider and approve Board Meeting intimation for consideration and approval of Unaudited
Friday, January 30, 2026	Intimation of violation under the Company's Code of Conduct for Regulating, Monitoring and Reporting of Insider Trading in securities and the SEBI (Prohibition of Insider Trading) Regulations, 2015
Monday, February 2, 2026	Board approved the unaudited standalone and consolidated financial results along with limited review reports of the Company for the third quarter and nine months ended December 31, 2025.
Monday, February 2, 2026	Press Release on financial results for Q3FY26
Monday, February 2, 2026	Credit Rating – Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Tuesday, February 3, 2026	Newspaper Publication of Unaudited Financial Results for the third quarter and nine months ended December 31, 2025
Monday, March 30, 2026	CORONA Remedies Limited has informed the Exchange regarding a press release dated March 30, 2026, titled CORONA Remedies announces strategic acquisition of Wokadine® in India
Monday, March 30, 2026	Board meeting for the approval of the following: (i) audited Standalone and Consolidated Financial Results along with Audit Reports of the Company for the fourth quarter and year ended March 31, 2026; (ii) recommended final dividend of 10/- (100%) per equity share of face value of ₹8377; 10/- each to the shareholders for their approval at the ensuing Annual General Meeting of the Company; (iii) appointment of M/s. Walker Chandio & Co LLP, Chartered Accountants as Statutory Auditor of the Company; (iv) re-appointment of M/s. Dhara Patel, peer reviewed Company Secretary Firm as the Secretarial Auditor of the Company; (v) appointment of M/s. Shah & Shah Associates, Chartered Accountants as Internal Auditor of the Company for the Financial Year 2026-27; (vi) re-appointment of M/s. Manish B. Analkat, as Cost Auditor of the Company for the Financial Year 2026-27; (vii) re-appointment of Dr. Kirtikumra Mehta (DIN: 00385658) as Non Executive Director and Chairman of the Company, for a term of five (5) consecutive Financial Years with effect from April 01, 2027
Monday, May 11, 2026	
Thursday, May 21, 2026	CORONA Remedies Limited has informed the Exchange regarding 'Communication to Shareholders - Intimation on Tax Deduction on Dividend'.
Thursday, May 28, 2026	CORONA Remedies Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Press Release - Receipt of EU-GMP Certificate".

Note: The Company meets Investors/ Analysts/ Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the schedule of such meetings and related details, as applicable. For further updates and information, please refer to the website of the Stock Exchanges i.e. [www.bseindia.com](http://www.bseindia.com) and / or [www.nseindia.com](http://www.nseindia.com)